Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127538 | 0.88 | CHRM3 (0.52) | CHRM3CHRM2CHRM1CHRM4NPC1 | |
| SCHEMBL3634718 | 0.85 | CHRM3 (0.49) | CHRM3CHRM2CHRM1CHRM4NPC1 | |
| SCHEMBL3617204 | 0.82 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4NPC1 | |
| SCHEMBL5334364 | 0.82 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4NPC1 | |
| SCHEMBL1086681 | 0.81 | KEAP1 (0.57) | CHRM3CHRM2CHRM1CHRM4GAA | |
| SCHEMBL4968719 | 0.81 | KEAP1 (0.57) | CHRM3CHRM2CHRM1CHRM4GAA | |
| SCHEMBL3101388 | 0.81 | KEAP1 (0.57) | CHRM3CHRM2CHRM1CHRM4GAA | |
| SCHEMBL1234072 | 0.81 | CHRM3 (0.56) | CHRM3CHRM2CHRM1CHRM4GAA | |
| SCHEMBL2795334 | 0.81 | KEAP1 (0.57) | CHRM3CHRM2CHRM1CHRM4GAA | |
| SCHEMBL14408507 | 0.80 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216971-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8815907-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CHRM3 4/4885CHRM2 1/4885CHRM1 3/4885 |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CHRM3 4/4885CHRM2 1/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.